Trial Profile
Recombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2021
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary) ; Calcitriol
- Indications Hypoparathyroidism
- Focus Therapeutic Use
- 01 Apr 2021 Status changed from recruiting to completed, according to Results published in the Endocrine.
- 26 Feb 2018 New trial record